Gubra A/S (GUBRA) — Denmark Stock Chart & News | StockAdder

(GUBRA)

Gubra A/S

Live chart and latest GUBRA stock news.

Market ETF → EDEN Denmark

Chart powered byTradingView— professional charts for every trader.Try it free →

GUBRA News

TradingView — Track All Markets

GUBRA: Record earnings and cash flow in 2025 fueled by AbbVie deal and robust Biotech pipeline

Feb 26, 2026 Stock Titan

Long-acting GLP-1 antagonist named for rare post-bariatric hypoglycemia

Jan 8, 2026 Bloomberg.com

European Obesity Stocks Join Healthcare Rally as AI Trade Ebbs

Nov 14, 2025 simplywall.st

Gubra A/S (CPH:GUBRA) Top Key Executive Niels Vrang, the company's largest shareholder sees 13%reduction in holdings value

Aug 3, 2025 TradingView — Track All Markets

GUBRA: Record earnings from AbbVie deal, strong cash, and major ESG progress define 2025

Feb 26, 2026 Yahoo Finance

Assessing Whether Gubra (CPSE:GUBRA) Looks Undervalued After Recent Share Price Gains

Jan 22, 2026 PR Newswire

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

Mar 3, 2025 FirstWord Pharma

AbbVie shares early weight-loss data for Gubra-partnered amylin analogue

Mar 9, 2026 marketscreener.com

Gubra A/S: Target Price Consensus and Analysts Recommendations | GUBR.F | DK0062266474

Apr 7, 2025 TradingView — Track All Markets

GUBRA: Record revenue and profit in 2025, led by AbbVie deal and strong Biotech performance

Feb 26, 2026 BioWorld News

Gubra files CTA for GUB-UCN2 for weight loss

Feb 27, 2026 Investing.com

Gubra H1 2025 slides: AbbVie deal drives record revenue, GUBamy shows strong results

Aug 21, 2025 Bloomberg.com

AbbVie Enters Obesity Market With Up to $2.2 Billion Gubra Deal

Mar 3, 2025 BioWorld News

Abbvie enters $2.2B deal for Gubra’s amylin obesity drug

Mar 3, 2025 Yahoo Finance

Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases